Boston, MA 05/23/2014 (wallstreetpr) – Innovative medical solutions provider, Boston Scientific Corporation (NYSE:BSX) announced that it could see positive performance on EVOLVE clinical study. The company disclosed that it continues to indicate assurance about safety and efficacy.
Evolve
The company revealed a favorable follow-up data during the three year period on EVOLVE clinical study that consists of performance and safety of the SYNERGY Everolimus – Eluting Bioabsorbable Polymer Platinum Chromium or PtCr Coronary stent system compared to the PROMUS element Stent system.
Boston Scientific Corporation (NYSE:BSX) said that the data was presented by director of MonashHeart Ian Meredith at EuroPCR 2014 in Melbourne, Australia. The company indicated that the primary experimental and angiographic endpoints of the trial were already published.
The company said that its EVOLVE II is a worldwide, multicenter, controlled, randomized pivotal trial with 1,684 patients enrolled across 125 sites globally. This includes the U.S., Canada, Australia, New Zealand, Europe, Japan and Singapore. Boston Scientific Corporation indicated that it is willing to support additional studies to evaluate outcomes, including a possibility for reducing dual ant platelet analysis. The company added that its SYNERGY Stent System is being scrutinized in multiple real-world independent studies throughout the spectrum of cardiovascular syndrome density.
SYNERGY Stent System
Meredith said that the SYNERGY stent results of three years based on the EVOLVE study continues to indicate promise with regard to efficacy and safety. He added, “Target lesion revascularization remains very low, at a rate of 1.1 percent, while there is no stent thrombosis in the SYNERGY full-dose arm at three years.”
Boston Scientific Corporation (NYSE:BSX) said that the EVOLVE clinical study data help the theory that this innovative polymer stent technology may perhaps permit improved healing during the durable polymer DES. In Japan and the U.S., the SYNERGY Stent System is a new device, and it is yet to reach the market.
The company has also expanded its commercial promotion of the SYNERGY Stent System in select places in Asia and Europe.
